RBP4 and ovarian cancer: In addition, RBP4 was shown to drive ovarian cancer cell migration [40]; pretreatment plasma D-dimer levels were associated with chemoresistance and poor disease outcome [41,42]; and low expression of kallistatin was associated with unfavorable prognosis, platinum resistance, and relapse [43].